BackgroundThe Tri-Score is a surgical risk model developed to predict outcomes after isolated tricuspid valve surgery. Its prognostic value across contemporary treatment strategies, including transcatheter interventions and medical therapy, remains uncertain.MethodsIn this retrospective multicenter cohort study, 104 patients treated between 2010 and 2024 for isolated ≥moderate tricuspid regurgitation (TR) were included. Patients were managed with medical therapy (n=31), surgery (n=40), or transcatheter edge-to-edge repair (T-TEER; n=33). The primary endpoint was all-cause mortality during follow-up, and the secondary endpoint was a composite of all-cause mortality or heart failure hospitalization. Outcomes were analyzed according to baseline Tri-Score categories: low (0–3), intermediate (4–5), and high (≥6). Multivariable Cox regression adjusted for treatment strategy, age, and sex.ResultsMean age was 74.8±12.9 years, and 62% were female. Median follow-up was 45 months (IQR 27–63). TR reduction to <moderate at one year occurred in 39% of medically treated patients, 92% of surgical patients, and 70% of T-TEER patients. One-year mortality increased across Tri-Score categories (6%, 13%, and 33% for low, intermediate, and high risk; log-rank p<0.001). The Tri-Score independently predicted mortality (HR 1.23 per point; 95% CI 1.08–1.40) and the composite endpoint (HR 1.34 per point; 95% CI 1.17–1.52).ConclusionsThe Tri-Score is an independent predictor of adverse outcomes in isolated ≥moderate TR, irrespective of treatment modality. As such, it supports early risk stratification and may help guide the timing of therapeutic interventions. Early intervention at low Tri-Scores results in excellent outcomes, whereas high-risk patients warrant tailored, multidisciplinary evaluation.